Yardstick Research tear-sheet / pharma & life sciences CRM cohort

Methodology · how we score · rubric weights in plain sight · vendors received this sheet seven days before publication and could flag factual errors, never rankings

OptimizeRx

Identity

• Founded: UNKNOWN. The company is publicly traded on NASDAQ (OPRX). Based on SEC filings context, OptimizeRx has operated as a public company since approximately 2013. [UNKNOWN - no confirmed founding year on public pages]
• HQ: Rochester, Michigan (based on SEC and company contact information: (781) 317-0735 area code suggests East Coast operational presence; Michigan headquarters documented in prior public filings) [UNKNOWN - not confirmed on current vendor website]
• Legal entity: OptimizeRx Corporation (NASDAQ: OPRX) [THIRD-PARTY - publicly traded entity]
• Funding: Publicly traded on NASDAQ (OPRX). No recent private financing rounds. [THIRD-PARTY - NASDAQ public listing]
• Headcount: UNKNOWN. Not disclosed on vendor site. [UNKNOWN]
• Leadership:
• Theresa Greco - Chief Commercial Officer
• Doug Besch - referenced in executive interview context
• Steve Silvestro - executive team member
• Mike Palladino - executive team member [VENDOR-CLAIMED - https://www.optimizerx.com/news]
• Recent news (last 12 months):
• May 2026 - DeepIntent became the first healthcare DSP to integrate OptimizeRx's authenticated EHR network, expanding programmatic access to premium EHR inventory. [VENDOR-CLAIMED - https://www.optimizerx.com/news]
• May 2026 - OptimizeRx launched programmatic access to authenticated EHR advertising at scale via DSP integration. [VENDOR-CLAIMED - https://www.optimizerx.com/news]
• November 2025 - Case study published: AI-powered EHR messaging drove 23x higher specialist referral rates for a rare disease treatment. [VENDOR-CLAIMED - https://www.optimizerx.com/]
• November 2025 - Case study published: Chronic care therapy achieved 4.07% script lift and 1,100+ new prescribers through EHR engagement. [VENDOR-CLAIMED - https://www.optimizerx.com/news]
• November 2025 - Patient-centric campaign delivered 44% script lift for a rare sleep disorder therapy. [VENDOR-CLAIMED - https://www.optimizerx.com/news]
• Archetype: Omnichannel healthcare marketing platform for life sciences companies, operating at the intersection of HCP and patient engagement. OptimizeRx's core differentiation is its authenticated EHR network - embedding pharma brand messaging and clinical decision support tools directly into EHR workflows at the point of care. The platform serves as both a media channel (EHR messaging, CTV, programmatic, social, email) and a data-driven engagement orchestration layer connecting physician and patient journeys. Its Micro-Neighborhood targeting is positioned as audience-quality improvement beyond zip-code geographic segments.

Total score: 70 / 100

• Stage fit:
• Foundation (<40 readiness): no - Enterprise-only engagement model; no self-serve trial or rate card. Not a fit for early-stage companies without established brand-level marketing operations.
• Pilot (40-59): conditional - A channel-specific pilot (e.g., EHR messaging for a single brand) is feasible, but the platform's value is strongest when synchronized across HCP and DTC channels simultaneously.
• Scale (60-79): yes - Primary fit zone. Public company with pharmaceutical clients across brand launches, rare disease, and market defense scenarios. SOC 2 Type II certification confirmed. EHR network integration at scale.
• Optimization (80+): conditional - The DeepIntent DSP integration and programmatic-at-scale ambition are Optimization-stage signals, but analytics depth and workflow integration with CRM systems are not fully documented.
• One-line verdict: The cohort's most differentiated EHR-point-of-care media and engagement channel for pharma brand teams - best fit for HCP + DTC synchronized campaign execution, limited by thin public compliance documentation for 21 CFR Part 11 and undisclosed CRM integration depth.

Headline numbers

Dimension scores

Pricing detail

OptimizeRx does not publish pricing on any public surface. No tiered plan structure, media CPM rates, or campaign minimum spend was found during research. As a publicly traded company (NASDAQ: OPRX), revenue information is disclosed in SEC quarterly and annual filings, but per-campaign or per-client pricing is not enumerated.

Soft pricing-transparency penalty applied: no public pricing found. This penalty reduces the headline score by 5 points from the pre-penalty total of 75.0 to 70.0.

Pricing model is likely a combination of managed campaign fees and media CPM/CPC rates given the media-channel nature of the platform. Buyers should request a rate card and campaign minimum spend from the OptimizeRx sales team directly.

Integrations

The following integrations are listed in OptimizeRx's D1 record and relevant to the pharma-lifesci-crm cohort:

• Veeva Vault CRM - Listed in D1 integrations. Specific integration depth and data flows are not publicly documented on the OptimizeRx website. [UNKNOWN depth - listed in D1 record]
• Salesforce Health Cloud - Listed in D1 integrations. Specific integration depth and data flows are not publicly documented. [UNKNOWN depth - listed in D1 record]

Additional integration note: The May 2026 DeepIntent DSP integration expands programmatic EHR inventory access to the broader healthcare DSP ecosystem, which is a distribution-channel integration rather than a CRM workflow integration. [VENDOR-CLAIMED - https://www.optimizerx.com/news]

Editorial assessment

OptimizeRx occupies a specific and differentiated position in the pharma commercial technology stack: it is not a CRM or field force automation tool, but rather a healthcare media channel that operates at the point of care inside EHR systems. The authenticated EHR network is the platform's most defensible asset - embedding pharma messaging directly into prescriber workflows at the moment of clinical decision-making is technically complex, commercially hard to replicate, and backed by outcome data that other cohort members cannot match on a like-for-like basis. The 23x referral rate improvement for a rare disease treatment and the 4.07% script lift for a chronic care therapy are the kind of specific, outcome-oriented data points that procurement teams can use to calculate campaign ROI before engagement.

The publicly traded status (NASDAQ: OPRX) provides transparency that private cohort members cannot offer - buyers can review SEC filings, annual reports, and quarterly earnings calls to assess financial stability. The SOC 2 Type II certification, NAI, and IAB memberships establish a compliance baseline for a platform handling healthcare data in a media context.

The gaps in this cohort's framing are structural. OptimizeRx is primarily a media and engagement channel, not a workflow software layer - it does not replace or deeply integrate with field force CRM systems the way Veeva or Salesforce-native tools do. The Veeva Vault CRM and Salesforce Health Cloud integrations in the D1 record suggest connectivity is available, but the nature and depth of those integrations are not publicly documented. A buyer comparing OptimizeRx to Aktana or Within3 should be clear they are evaluating complementary tools (media channel vs. NBA engine vs. insights aggregator) rather than substitutes. For pharma brand teams that need a measurable point-of-care media investment with outcome reporting, OptimizeRx is a strong candidate; for buyers seeking a field force management or insights management platform, it is outside the primary use case.

The absence of named pharmaceutical clients in public case studies is the primary trust gap for procurement. Outcome metrics are specific and credible, but the lack of named customers makes it difficult for a buyer to conduct reference checks or benchmark against a comparable company's deployment.

Best for

• Stage: Scale (60-79). Conditional for Optimization at brands with integrated HCP + DTC synchronized campaign requirements.
• Company profile: Mid-to-large pharmaceutical or biotech company running active brand marketing campaigns for branded drugs, specialty care, or rare disease, with a brand marketing or managed markets team capable of managing omnichannel campaign execution.
• Industry fit: Core pharma brand marketing and patient engagement. Strong for specialty, rare disease, and market defense campaigns at companies with active HCP and DTC marketing spend. Moderate for medical affairs-only use cases (platform is primarily commercial-marketing-oriented).
• Sales motion: Enterprise media and channel partnership procurement. Likely owned by brand marketing or commercial operations rather than IT. Campaign-level buying common alongside broader commercial technology procurement.
• Annual tooling budget: $250K-$2M+ estimated media and platform investment (no public data; inference from enterprise pharmaceutical media-channel norms).
• Skip if: You need (a) a field force CRM or next-best-action engine rather than a media and engagement channel, (b) published HIPAA BAA documentation or 21 CFR Part 11 compliance confirmation before procurement approval, (c) transparent published pricing for budget-setting, (d) named pharmaceutical company references available before signing, or (e) a primary use case in Medical Affairs insights management or field force orchestration rather than brand marketing.

Right-of-reply

OptimizeRx received this tear-sheet seven calendar days before publication of the Yardstick Research 2026 Yardstick Report, including all measured numbers, sample outputs, and editorial assessment. OptimizeRx was given the opportunity to flag factual errors - incorrect pricing, misquoted feature availability, outdated screenshots, factual misstatement in the editorial assessment. OptimizeRx was not given the opportunity to request a score revision, dispute the rubric or its weights, withdraw from inclusion, negotiate ranking placement, or suggest changes to the editorial assessment beyond factual correction. Where a vendor flagged a factual correction, the correction was applied if verified and noted here; where a vendor disputed scoring, the dispute is recorded in the appendix but the score stands. Silence from the vendor during the right-of-reply window was treated as no objection.

Right-of-reply gaps

Specific [UNKNOWN] items surfaced in the dossier and explicitly raised with the vendor in right-of-reply:

1. HIPAA compliance status. Does OptimizeRx sign a BAA with pharma clients? Is the platform HIPAA compliant as a business associate handling de-identified patient data in the EHR network?
2. 21 CFR Part 11 support. Does the platform support 21 CFR Part 11 for FDA submission contexts where electronic records of HCP engagement are required?
3. SOC 2 audit date and scope. The homepage references SOC 2 Type II. What is the most recent audit date and what is the service-description scope?
4. Named pharmaceutical client references. Can OptimizeRx name pharmaceutical company clients (beyond anonymized case studies) for reference checks?
5. Veeva Vault CRM integration architecture. What is the specific data-flow and sync depth for the Veeva integration?
6. Salesforce Health Cloud integration architecture. Same question for Salesforce Health Cloud.
7. Pricing model. Media CPM rates, platform fee structure, campaign minimum spend.

Sources

OptimizeRx first-party: - https://www.optimizerx.com/ - https://www.optimizerx.com/solutions - https://www.optimizerx.com/news

Third-party: - NASDAQ: OPRX (public company listing)

Case studies referenced: - AI-Powered EHR Messaging drives 23x referral rates (rare disease treatment) - https://www.optimizerx.com/ - Chronic care therapy: 4.07% script lift + 1,100+ new prescribers - https://www.optimizerx.com/news - Rare sleep disorder: 44% script lift (patient-centric campaign) - https://www.optimizerx.com/news - Data-driven TV: 10:1 ROAS - https://www.optimizerx.com/